23 Jul, 2026
According to Straits Research, the global spinal cord stimulation market valued at $3.39 billion in 2025, is projected to grow from $3.65 billion in 2026 to $6.7 billion by 2034 at a CAGR of 7.88% during the forecast period 2026–2034.
Spinal Cord Stimulation (SCS) is a therapeutic approach used to alleviate chronic pain, particularly in the back, legs, or arms. The procedure involves placing a small device near the spinal cord, which delivers gentle electrical pulses. These pulses disrupt the transmission of pain signals to the brain, helping to reduce the perception of pain. SCS is generally considered for individuals who have not experienced sufficient relief from medications or surgical interventions. This treatment is both adjustable and reversible, offering a significant improvement in quality of life for those suffering from ongoing or nerve-related pain.
The increasing incidence of chronic pain conditions is a key factor driving the growth of the spinal cord stimulation market, as more patients turn to long-term solutions when traditional treatments prove ineffective. Conditions such as failed back surgery syndrome (FBSS) and complex regional pain syndrome (CRPS) are now commonly treated with spinal cord stimulation, owing to its proven ability to alleviate pain and enhance mobility.
With the prevalence of these disorders on the rise, the demand for advanced neuromodulation techniques like spinal cord stimulators is anticipated to increase consistently in the coming years.
A key growth opportunity in the global spinal cord stimulation market is the development of non-invasive or minimally invasive stimulation systems, which aim to reduce surgical risks and improve treatment accessibility. These cutting-edge technologies are especially beneficial for patients who are not eligible for traditional implantable devices.
These advancements reflect a broader industry trend toward safer, more user-friendly neuromodulation solutions that enhance patient outcomes while helping to lower overall healthcare costs.
North America holds a leading position in the global spinal cord stimulation market, supported by its well-established healthcare infrastructure, favorable insurance coverage, and widespread awareness of neuromodulation treatments. The United States, in particular, experiences high adoption rates due to the increasing incidence of chronic pain conditions like failed back surgery syndrome and diabetic neuropathy. As reported by the CDC, around 20% of U.S. adults are affected by chronic pain, which drives the demand for spinal cord stimulators.
Moreover, major industry players such as Boston Scientific and Medtronic, both based in the region, continue to introduce advanced technologies, including Medtronic’s Intellis™ platform. The availability of skilled neurosurgeons and dedicated pain management centers ensures greater patient access to these cutting-edge therapies, further strengthening North America's dominance in the market.
sales@straitsresearch.com